Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Aug 5;8(8):CD006570.
doi: 10.1002/14651858.CD006570.pub3.

Benzodiazepines for catatonia in people with schizophrenia or other serious mental illnesses

Hadar Zaman  1 , Roger Carl Gibson, Geoffrey Walcott
Affiliations

Benzodiazepines for catatonia in people with schizophrenia or other serious mental illnesses

Hadar Zaman et al. Cochrane Database Syst Rev. .

Abstract

Background: Catatonia is a debilitating disorder of movement and volition associated with schizophrenia and some other mental illnesses. People with catatonia are more likely to require hospitalisation and highly supervised care than those without the disorder. They also have an increased risk of secondary complications such as pneumonia, malnutrition and dehydration. The mainstay of treatment has been drug therapies and electroconvulsive therapy.

Objectives: To compare the effects of benzodiazepines with other drugs, placebo or electroconvulsive therapy for catatonia in people with schizophrenia or other similar serious mental illnesses (SMIs).

Search methods: We updated our previous search (28 February 2007) by searching the Cochrane Schizophrenia Group's Study-Based Register of Trials (9 November 2016; 6 February 2019). This register is compiled by systematic searches of major resources (including CENTRAL, MEDLINE, Embase, AMED, BIOSIS, CINAHL, PsycINFO, PubMed, and registries of clinical trials) and their monthly updates, handsearches, grey literature, and conference proceedings, with no language, date, document type, or publication status limitations for inclusion of records into the register. We also manually searched reference lists from studies selected by the search.

Selection criteria: All controlled clinical trials that randomised people who have schizophrenia or other similar SMI and experiencing catatonia to receive benzodiazepines or another relevant treatment. We included studies that met our inclusion criteria and reported usable data. We excluded those not meeting our inclusion criteria or those not reporting usable data. We contacted authors when we required further information; and if we received no response, we put those studies aside as 'awaiting assessment'.

Data collection and analysis: Review authors extracted data independently. For dichotomous data we calculated relative risks (RR) and their 95% confidence intervals (CI) on an intention-to-treat basis using a fixed-effect model. We completed a 'Risk of bias' assessment for the included study and generated a 'Summary of findings' table using GRADE.

Main results: The searches found 130 citations, from which we could identify 22 possibly relevant studies. From these, we could only include one study. This study had a relatively small sample size of 17 participants who received lorazepam or oxazepam and were drug free for one week before the trial started. The only usable data reported by this study were clinically important change in symptoms of catatonia measured as 50% improvement on the Visual Analogue Scale (VAS). There was no difference in the numbers of participants showing a clinically important change in their catatonic symptoms (RR 0.95, 95% CI 0.42 to 2.16; participants = 17; studies = 1; very low quality evidence).No data were reported for other important outcomes of hospital stay, clinically important change in satisfaction with care, global state, adverse effects or general functioningWe did find a few studies meeting our inclusion criteria but they reported no usable data. We had to exclude these. Although poorly reported, these studies do illustrate that relevant studies have been undertaken - they are not impossible to design and conduct.

Authors' conclusions: Analysis of the results from this review, which was a head-to-head comparison of two benzodiazepine monotherapies, does not show a clear difference in effect. No data were available for benzodiazepines compared to placebo or standard care. The lack of usable data and very low quality of data available makes it impossible to draw firm conclusions and further studies with a high-quality methodology and reporting are required in order to determine more definitively the outcomes associated with benzodiazepine use in the clinical management of catatonia in persons with schizophrenia and other SMI.

PubMed Disclaimer

Conflict of interest statement

Hadar Zaman ‒ none.

Roger Gibson ‒ none.

Geoffery Walcott ‒ none.

Figures

1
1
Study flow diagram for searches up to February 2019
2
2
Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.
3
3
Risk of bias summary: review authors' judgements about each risk of bias item for each included study.
1.1
1.1. Analysis
Comparison 1 LORAZEPAM versus OXAZEPAM, Outcome 1 Catatonia: Clinically important change in symptoms (improved at least 50% on the VAS).
1.2
1.2. Analysis
Comparison 1 LORAZEPAM versus OXAZEPAM, Outcome 2 Catatonia: Any change in symptoms ‐ average total score (VAS, endpoint, high = poor).
See this image and copyright information in PMC

Update of

References

References to studies included in this review

Schmider 1999 {published data only}
    1. Schmider J, Standhart H, Deuschle M, Drancoli J, Heuser I. A double blind comparison of lorazepam and oxazepam in psychogenic catatonia. 10th European College of Neuropsychopharmacology Congress; 1997 Sep 13‐17; Vienna, Austria. 1997. [CSzG: Ref2662]
    1. Schmider J, Standhart H, Deuschle M, Drancoli J, Heuser I. A double blind comparison of lorazepam and oxazepam in psychomotor retardation and mutism. Biological Psychiatry 1999;46(3):437‐41. [CSzG: Ref5244; MEDLINE: ; EMBASE 1999252184] - PubMed

References to studies excluded from this review

Arioni 1971 {published data only}
    1. Arioni FBM, Gaston A, Pancheri P. Clinical experimentation with the new drug LM‐2717 [Sperimentazione clinica di un nuovo farmaco LM 2717]. Rivista di Psichiatria 1971;6(6):409‐94. [PsycINFO 1973‐23370‐001]
Barbee 1992 {published data only}
    1. Barbee JG, Mancuso DM, Freed CR, Todorov AA. Alprazolam as a neuroleptic adjunct in the emergency treatment of schizophrenia. American Journal of Psychiatry 1992;149:506‐10. [MEDLINE: ] - PubMed
Fischer 1974 {published data only}
    1. Fischer Cornelssen K, Ferner U, Steiner H. Multifocal psychopharmaceutic testing ("Multihospital trial") [Multifokale Psychopharmakaprufung ("Multihospital Trial")]. Arzneimittel‐Forschung 1974;24(10):1706‐24. [MEDLINE: ] - PubMed
Hekimian 1967 {published data only}
    1. Hekimian LJ, Friedhoff AJ. A controlled study of placebo, chlordiazepoxide and chlorpromazine with thirty male schizophrenic patients. Diseases of the Nervous System 1967;28(10):675‐8. [MEDLINE: ] - PubMed
Holden 1968 {published data only}
    1. Holden JM, Itil TM, Keskiner A, Fink M. Thioridazine and chlordiazepoxide, alone and combined, in the treatment of chronic schizophrenia. Comprehensive Psychiatry 1968;9(6):633‐43. [MEDLINE: ] - PubMed
Hu 2004 {published data only}
    1. 4. Investigation of administering BZD medicament in outpatients with psychosis. Heath Psychology 2004;12(1):43‐67. [116287]
Kunigiri 2002 {published data only}
    1. Girish K, Gill NS. Electroconvulsive therapy in lorazepam non‐responsive catatonia. Indian Journal of Psychiatry 2003;45:21‐5. - PMC - PubMed
    1. Kunigiri G, Gill NS, B GN, Naimmagadda J. Electroconvulsive therapy in lorazepam non‐responsive catatonia. 12th World Congress of Psychiatry; 2002 Aug 24‐29; Yokohama, Japan. 2002. [MEDLINE: ]
Kurland 1966 {published data only}
    1. Kurland AA, Bethon GD, Michaux MH, Agallianos DD. Chlorpromazine‐chlordiazepoxide and chlorpromazine‐imipramine treatment: side effects and clinical laboratory findings. Journal of New Drugs 1966;6:80‐95. [MEDLINE: ] - PubMed
Merlis 1962 {published data only}
    1. Merlis S, Turner WJ, Krumholz W. A double‐blind comparison of diazepam, chlordiazepoxide and chlorpromazine in psychotic patients. Journal of Neuropsychiatry 1962;3(Suppl 1):S133‐8. [PsycINFO 1977‐03995‐001] - PubMed
Patra 1998 {published data only}
    1. Patra A, Sarkar A, Kumar R. Outcome of lorazepam in catatonia oral vs parenteral administration. Indian Journal of Psychiatry 1998;40(Suppl):91.
Smith 1960 {published data only}
    1. Smith ME. A clinical study of chlorpromazine and chlordiazepoxide. Connecticut State Medical Journal 1961;25:153‐7.
    1. Smith ME. A comparative controlled study with chlordiazepoxide. American Journal of Psychiatry 1960;117:362‐3. [MEDLINE: ]
Ungvari 1997 {published data only}
    1. Ungvari GS, Chow LY, Chiu HFK, Lau B. Different treatment response of distinct schizophrenia subtypes: the group of systematic catatonias. 6th World Congress of Biological Psychiatry; 1997 Jun 22‐27; Nice, France. 1997.
Ungvari 1999 {published data only}
    1. Pang AHT, Ungvari G, Ng FS, Chiu H. Treatment response of systematic catatonia (leonhard) to lorazepam. 21st Collegium Internationale neuro‐Psychopharmacologicum Congress; 1998 Jul 12‐16; Glasgow, UK. 1998.
    1. Ungvari G, Pang A, Ng F, Chiu H, Wong C. Treatment response studies in systematic catatonia (leonhard). i. lorazepam challenge. 8th Congress of the Association of European Psychiatrists; 1996 Jul 7‐12; London, UK. 1996.
    1. Ungvari GS, Chiu HF, Chow LY, Lau BS, Tang WK. Lorazepam for chronic catatonia: a randomized, double blind, placebo controlled cross over study. Psychopharmacology 1999;142(4):393‐8. [MEDLINE: ] - PubMed
Vasquez‐Gomez 2001 {published data only}
    1. Vasquez‐Gomez F. The use of midazolam for control of acutely agitated outpatients in psychiatry emergency. 7th World Congress of Biological Psychiatry; 2001 Jul 1‐6; Berlin, Germany. 2001; Vol. 2, issue Suppl 1. [7th World Congress of Biological Psychiatry [CD‐ROM]: Conifer, Excerpta Medica Medical Communications BV, 2001 P034‐02]
Weckowicz 1960 {published data only}
    1. Weckowicz TE, Ward T. Clinical trial of RO 5‐0690 and chlorpromazine on disturbed chronic schizophrenic patients. Diseases of the Nervous System 1960;21:527‐8. [MEDLINE: ] - PubMed
Wetzel 1997 {published data only}
    1. Wetzel H, Klawe CJ, Muller MJ, Wiesner J, Benkert O. Lorazepam for stupor and mutism: a double‐blind placebo‐controlled cross‐over study. 10th European College of Neuropsychopharmacology Congress; 1997 Sep 13‐17; Vienna, Austria. 1997. [MEDLINE: ]
Wolkowitz 1988 {published data only}
    1. Wolkowitz OM, Breier A, Doran A, Kelsoe J, Lucas P, Paul SM, et al. Alprazolam augmentation of the antipsychotic effects of fluphenazine in schizophrenic patients ‐ preliminary results. Archives of General Psychiatry 1988;45(7):664‐71. [MEDLINE: ; PsycINFO 76‐02568] - PubMed
    1. WolkowitzOM, Pickar D, Doran AR, Breier A, Tarell J, Paul SM. Combination alprazolam‐neuroleptic treatment of the positive and negative symptoms of schizophrenia. American Journal of Psychiatry 1986;143(1):85‐7. - PubMed
Wolkowitz 1992 {published data only}
    1. Wolkowitz OM, Turetsky N, Reus VI, Hargreaves WA. Benzodiazepine augmentation of neuroleptics in treatment resistant schizophrenia. Psychopharmacology Bulletin 1992;28(3):291‐5. [MEDLINE: ; PsycINFO 80‐18793] - PubMed
Wolkowitz 1993 {published data only}
    1. Wolkowitz OM, Harris D, Turetsky NG, Reus VI, Johnson R, Gustafson M, et al. Alprazolam‐neuroleptic treatment of schizophrenia. 146th Annual Meeting of the American Psychiatric Association; 1993 May 22‐27; San Francisco, California, USA. 1993:119.
Wyant 1990 {published data only}
    1. Wyant M, Diamond BI, O'Neal E, Sloan A, Borison RL. The use of midazolam in acutely agitated psychiatric patients. Psychopharmacology Bulletin 1990;26(1):126‐9. [MEDLINE: ; PsycINFO 79‐28483] - PubMed

Additional references

Altman 1996
    1. Altman DG, Bland JM. Detecting skewness from summary information. BMJ 1996;313(7066):1200. - PMC - PubMed
APA 2000
    1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (DSM‐IV TR). 4th Edition. Washington: American Psychiatric Association, 2000.
Bland 1997
    1. Bland JM. Statistics notes. Trials randomised in clusters. BMJ 1997;315(7108):600. - PMC - PubMed
Boissel 1999
    1. Boissel JP, Cucherat M, Li W, Chatellier G, Gueyffier F, Buyse M, et al. The problem of therapeutic efficacy indices. 3. Comparison of the indices and their use [Aperçu sur la problématique des indices d'efficacité thérapeutique, 3: comparaison des indices et utilisation. Groupe d'Etude des Indices D'efficacite]. Therapie 1999;54(4):405‐11. [PUBMED: 10667106] - PubMed
Bush 1997
    1. Bush G, Petrides G, Francis A. Catatonia and other motor syndromes in a chronically hospitalized psychiatric population. Schizophrenia research 1997;27(1):83‐92. - PubMed
Daniels 2009
    1. Daniels, J. Catatonia: clinical aspects and neurobiological correlates. Journal of Neuropsychiatry and Clinical Neurosciences 2009;21(4):371‐80. - PubMed
Deeks 2000
    1. Deeks J. Issues in the selection for meta‐analyses of binary data. 8th International Cochrane Colloquium; 2000 Oct 25‐28; Cape Town. Cape Town: The Cochrane Collaboration, 2000.
Deeks 2011
    1. Deeks JJ, Higgins JPT, Altman DG, editor(s). Chapter 9: Analysing data and undertaking meta‐analyses. In: Higgins JPT, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.handbook.cochrane.org.
Dhossche 2016
    1. Dhossche DM, Wachtel LE, Goetz M, Sienaert P. Catatonia in psychiatric illnesses. In: Fatemi SH, Clayton PJ editor(s). The Medical Basis of Psychiatry. 4th Edition. New York: Springer, 2016:517‐35.
Divine 1992
    1. Divine GW, Brown JT, Frazier LM. The unit of analysis error in studies about physicians' patient care behavior. Journal of General Internal Medicine 1992;7(6):623‐9. - PubMed
Donner 2002
    1. Donner A, Klar N. Issues in the meta‐analysis of cluster randomized trials. Statistics in Medicine 2002;21(19):2971‐80. - PubMed
Egger 1997
    1. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta‐analysis detected by a simple, graphical test. BMJ 1997;315(7109):629‐34. - PMC - PubMed
Elbourne 2002
    1. Elbourne D, Altman DG, Higgins JP, Curtina F, Worthingtond HV, Vaile A. Meta‐analyses involving cross‐over trials: methodological issues. International Journal of Epidemiology 2002;31(1):140‐9. - PubMed
Ellul 2015
    1. Ellul P, Choucha W. Neurobiological approach of catatonia and treatment perspectives. Frontiers in Psychiatry / Frontiers Research Foundation 2015;6:182. - PMC - PubMed
Fink 2006
    1. Fink M, Taylor MA. Neuroleptic malignant syndrome is malignant catatonia, warranting treatments efficacious for catatonia. Progress in Neuro‐psychopharmacology & Biological Psychiatry 2006;6(30):1182‐3. - PubMed
Furukawa 2006
    1. Furukawa TA, Barbui C, Cipriani A, Brambilla P, Watanabe N. Imputing missing standard deviations in meta‐analyses can provide accurate results. Journal of Clinical Epidemiology 2006;59(1):7‐10. - PubMed
Gover 2011
    1. Grover S, Aggarwal M. Long‐term maintenance lorazepam for catatonia: a case report. General Hospital Psychiatry 2011;33(1):82. - PubMed
Gulliford 1999
    1. Gulliford MC. Components of variance and intraclass correlations for the design of community‐based surveys and intervention studies: data from the Health Survey for England 1994. American Journal of Epidemiology 1999;149(9):876‐83. - PubMed
Higgins 2003
    1. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta‐analyses. BMJ 2003;327(7414):557‐60. - PMC - PubMed
Higgins 2005
    1. Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions 4.2.5 [updated May 2005]. www.cochrane.org/resources/handbook/hbook.htm (accessed 04 February 2006).
Higgins 2011a
    1. Higgins JP, Green S, editor(s). Chapter 7: Selecting studies and collecting data. In: Higgins JP, Green S, (editors), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.
Higgins 2011b
    1. Higgins JP, Altman DG, Sterne JAC, editor(s). Chapter 8: Assessing risk of bias in included studies. In: Higgins JP, Green S, (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.
Hung 2006
    1. Hung YY, Huang TL. Lorazepam and diazepam rapidly relieve catatonic features in major depression. Clinical Neuropharmacology 2006;29(3):144‐7. - PubMed
Hutton 2009
    1. Hutton JL. Number needed to treat and number needed to harm are not the best way to report and assess the results of randomised clinical trials. British Journal of Haematology 2009;146(1):27‐30. [PUBMED: 19438480] - PubMed
Kahlbaum 1973
    1. Kahlbaum KL. Catatonia [Die Katatonie oder das spannungirresein]. Catatonia. Baltimore: Johns Hopkins University Press, 1973.
Kay 1986
    1. Kay SR, Opler LA, Fiszbein A. Positive and Negative Syndrome Scale (PANSS) Manual. North Tonawanda, NY: Multi‐Health Systems, 1986.
Lee 2000
    1. Lee JW, Schwartz DL, Hallmayer J. Catatonia in a psychiatric intensive care facility: incidence and response to benzodiazepines. Annals of Clinical Psychiatry 2000;12(2):88‐96. - PubMed
Leon 2006
    1. Leon AC, Mallinckrodt CH, Chuang‐Stein C, Archibald DG, Archer GE, Chartier K. Attrition in randomized controlled clinical trials: methodological issues in psychopharmacology. Biological Psychiatry 2006;59(11):1001‐5. [PUBMED: 16905632] - PubMed
Leucht 2005a
    1. Leucht S, Kane JM, Kissling W, Hamann J, Etschel E, Engel R. Clinical implications of Brief Psychiatric Rating Scale Scores. British Journal of Psychiatry 2005;187:366‐71. - PubMed
Leucht 2005b
    1. Leucht S, Kane JM, Kissling W, Hamann J, Etschel E, Engel RR. What does the PANSS mean?. Schizophrenia Research 2005;79(2‐3):231‐8. [PUBMED: 15982856] - PubMed
Marshall 2000
    1. Marshall M, Lockwood A, Bradley C, Adams C, Joy C, Fenton M. Unpublished rating scales: a major source of bias in randomised controlled trials of treatments for schizophrenia. British Journal of Psychiatry 2000;176:249‐52. - PubMed
Overall 1962
    1. Overall JE, Gorham DR. The Brief Psychiatric Rating Scale. Psychological Reports 1962;10:799‐812.
Penland 2006
    1. Penland HR, Weder N, Tampi RR. The catatonic dilemma expanded. Annals of General Psychiatry 2006;5:14. - PMC - PubMed
Regestein 1977
    1. Regestein QR, Alpert JS, Reich P. Sudden catatonic stupor with disastrous outcome. Journal of the American Medical Association 1977;238:618‐20. - PubMed
Rosebush 1990
    1. Rosebush PI, Hildebrand AM, Furlong BG, Mazurek MF. Catatonic syndrome in a general psychiatric inpatient population: frequency, clinical presentation, and response to lorazepam. Journal of Clinical Psychiatry 1990;51:357‐62. - PubMed
Rosebush 2010
    1. Rosebush PI, Mazurek, MF. Catatonia and its treatment. Schizophrenia Bulletin 2009;36(2):239‐42. - PMC - PubMed
Schünemann 2008
    1. Schünemann HJ, Oxman AD, Vist GE, Higgins JPT, Deeks JJ, Glasziou P, et al. Chapter 12: Interpreting results and drawing conclusions. In Higgins JPT, Green S, editor(s), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.
Shokraneh 2017
    1. Shokraneh F, Adams CE. Study‐based registers of randomized controlled trials: Starting a systematic review with data extraction or meta‐analysis. BioImpacts 2017;7(4):209‐17. [DOI: 10.15171/bi.2017.25] - DOI - PMC - PubMed
Smith 1961
    1. Smith ME. A clinical study of chlorpromazine and chlordiazepoxide. Connecticut State Medical Journal 1961;25:153‐7.
Sterne 2011
    1. Sterne JAC, Egger M, Moher D, editor(s). Chapter 10: Addressing reporting biases. In: Higgins JPT, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Intervention. Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.
Ukoumunne 1999
    1. Ukoumunne OC, Gulliford MC, Chinn S, Sterne JAC, Burney PGJ. Methods for evaluating area‐wide and organistation‐based intervention in health and health care: a systematic review. Health Technology Assessment 1999;3(5):iii‐92. - PubMed
WHO 1992
    1. World Health Organization. ICD‐10: international statistical classification of diseases and related health problems. Geneva: World Health Association, 1992.
Xia 2009
    1. Xia J, Adams CE, Bhagat N, Bhagat V, Bhoopathi P, El‐Sayeh H, et al. Loss to outcomes stakeholder survey: the LOSS study. Psychiatric Bulletin 2009;33(7):254‐7.

Publication types

MeSH terms

LinkOut - more resources